NEOSTAR trial and the current status of neoadjuvant therapy in non-small cell lung cancer

J Thorac Cardiovasc Surg. 2024 Jun;167(6):1936-1942. doi: 10.1016/j.jtcvs.2023.10.055. Epub 2023 Nov 1.

Authors

Boris Sepesi¹, Reza Mehran², Jonathan Spicer³, Tina Cascone⁴

Affiliations

¹ Houston, Tex. Electronic address: [email protected].
² Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, Tex.
³ Division of Thoracic Surgery, McGill University Health Center, Montreal, Quebec, Canada.
⁴ Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Tex.

PMID: 37923289
DOI: 10.1016/j.jtcvs.2023.10.055

No abstract available

Keywords: NSCLC; chemotherapy; clinical trials; immunotherapy; neoadjuvant therapy; perioperative therapy; review.

Publication types

Editorial

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / mortality
Carcinoma, Non-Small-Cell Lung* / pathology
Carcinoma, Non-Small-Cell Lung* / therapy
Chemotherapy, Adjuvant
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / mortality
Lung Neoplasms* / pathology
Lung Neoplasms* / therapy
Neoadjuvant Therapy* / adverse effects
Pneumonectomy* / adverse effects
Treatment Outcome